佐治亚州阿尔法利塔 - Clearside Biomedical, Inc. (NASDAQ: CLSD )周三宣布，加拿大卫生部已批准XIPERE（曲安奈德注射混悬液）用于治疗葡萄膜炎性黄斑水肿（UME）。这家目前市值为2730万美元的生物技术公司，尽管近期市场面临挑战，但仍保持着89.45%的高毛利率。根据 InvestingPro 分析，基于其公允价值估计，该股票目前被低估。

Fintel reports that on July 18, 2025, Chardan Capital downgraded their outlook for Clearside Biomedical (NasdaqGM:CLSD) from ...

Review the current Clearside Biomedical Inc (CLSD:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if CLSD is the best investment for you.

我在模拟交易比赛#2025美股模拟交易第三季度赛#，成功以价格0.540委托买入了$CLSD CLSD$～跟我一起入圈模拟交易，每周都有惊喜奖励！

CLEARSIDE BIOMEDICAL ($CLSD) posted quarterly earnings results on Thursday, March 27th. The company reported earnings of -$0.10 per share, missing estimates of -$0.10 by $0.00.

Clearside Biomedical, Inc. (NASDAQ: CLSD) Q3 2023 Results Conference Call November 13, 2023 4:30 PM ET Company Participants Jenny Kobin - IR George Lasezkay - CEO Charlie Deignan - CFO Conference ...

Clearside Biomedical (NASDAQ:CLSD) just reported results for the first quarter of 2024. Clearside Biomedical reported earnings per share of -17 cents. This was below the analyst estimate for EPS ...

Clay Thorp, a director at $CLSD, bought 15,000 shares of the company on 02-24-2025 for an estimated $13,800. This trade was reported by Quiver Quantitative using data from a recent SEC filing.